These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23523344)

  • 41. Prevalence of natural health product use in healthy postmenopausal women.
    Daoust JL; Mercer LC; Duncan AM
    Menopause; 2006; 13(2):241-50. PubMed ID: 16645538
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Harmony in drug regulation, but who's calling the tune? An examination of regulatory harmonization in health Canada.
    Lexchin J
    Int J Health Serv; 2012; 42(1):119-36. PubMed ID: 22403914
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Food and Drug Administration regulations and licensure.
    Barker LF
    Fed Proc; 1975 May; 34(6):1522-4. PubMed ID: 1126452
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Partnerships and communities in English drug policy: the challenge of deprivation.
    Macgregor S; Thickett A
    Int J Drug Policy; 2011 Nov; 22(6):478-90. PubMed ID: 21890338
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of cGMP compliance on consumer confidence in dietary supplement products.
    Crowley R; FitzGerald LH
    Toxicology; 2006 Apr; 221(1):9-16. PubMed ID: 16469425
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The regulation of cell therapy products in Canada.
    Ridgway AA
    Biologicals; 2015 Sep; 43(5):406-9. PubMed ID: 26141550
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of implementation of the Canadian regulatory requirements on the quality of natural health products: the glucosamine case.
    Aghazadeh-Habashi A; Duke J; Jamali F
    J Pharm Pharm Sci; 2014; 17(1):20-4. PubMed ID: 24735759
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthetic Biology in the FDA Realm: Toward Productive Oversight Assessment.
    Fatehi L; Hall RF
    Food Drug Law J; 2015; 70(2):339-69, iii-iv. PubMed ID: 26302603
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Natural Health Products and Diabetes: A Practical Review.
    Necyk C; Zubach-Cassano L
    Can J Diabetes; 2017 Dec; 41(6):642-647. PubMed ID: 28826695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of natural health products by paediatric patients in respite care.
    Beringer A; Vaillancourt R; Villarreal G; Vadeboncoeur C
    Paediatr Child Health; 2015; 20(1):23-9. PubMed ID: 25722640
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Canada's new law strengthens drug regulatory powers but is vague on mandatory trial registration.
    Dyer O
    BMJ; 2014 Nov; 349():g6620. PubMed ID: 25366329
    [No Abstract]   [Full Text] [Related]  

  • 54. Potential interactions between pharmaceuticals and natural health products in Canada.
    Singh SR; Levine MA
    J Clin Pharmacol; 2007 Feb; 47(2):249-58. PubMed ID: 17244776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Regulatory Review Process in South Africa: Challenges and Opportunities for a New Improved System.
    Keyter A; Gouws J; Salek S; Walker S
    Ther Innov Regul Sci; 2018 Jul; 52(4):449-458. PubMed ID: 29848046
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Science across borders: 5th annual natural health product research conference-march 26-29, 2008, toronto, Canada.
    Ghayur MN
    Evid Based Complement Alternat Med; 2010 Sep; 7(3):391-5. PubMed ID: 18955362
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epidemiology of NHP-drug interactions: identification and evaluation.
    Brulotte J; Vohra S
    Curr Drug Metab; 2008 Dec; 9(10):1049-54. PubMed ID: 19075621
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regulatory oversight of human pathogens and toxins in Canada.
    Labrie C; Lecordier S
    Can Commun Dis Rep; 2015 Dec; 41(Suppl 6):14-18. PubMed ID: 29769973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CANADA'S NEW DRUG REGULATIONS.
    WARNER P; GLASSCO A; KROEKER J
    Can Med Assoc J; 1964 Feb; 90(8):540-1. PubMed ID: 14118696
    [No Abstract]   [Full Text] [Related]  

  • 60. The Canadian Natural Health Products (NHP) regulations: industry compliance motivations.
    Laeeque H; Boon H; Kachan N; Cohen JC; D'Cruz J
    Evid Based Complement Alternat Med; 2007 Jun; 4(2):257-62. PubMed ID: 17549245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.